Recent News

• 03.12.2026 - Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.05.2026 - Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
• 02.23.2026 - Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 01.23.2026 - Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
• 01.22.2026 - Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
• 01.20.2026 - Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 01.16.2026 - Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Recent Filings

• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.27.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.23.2026 - 8-K Current report
• 01.21.2026 - S-3MEF Registration adding securities to prior Form S-3 registration [Rule 462(b)]
• 01.20.2026 - 8-K Current report
• 01.20.2026 - 424B5 Prospectus [Rule 424(b)(5)]